The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Y-mAbs Therapeutics's share price is $14.71.
Y-mAbs Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.94. Hence, Y-mAbs Therapeutics's PS Ratio for today is 7.57.
The historical rank and industry rank for Y-mAbs Therapeutics's PS Ratio or its related term are showing as below:
YMAB'
s PS Ratio Range Over the Past 10 Years
Min: 2.03 Med: 11.2 Max: 100.29
Current: 7.67
During the past 8 years, Y-mAbs Therapeutics's highest PS Ratio was 100.29. The lowest was 2.03. And the median was 11.20.
YMAB's PS Ratio is ranked better than 53.47% of 993
companies
in the Biotechnology industry
Industry Median: 8.92
vs YMAB: 7.67
During the past 8 years, Y-mAbs Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 55.50% per year. The lowest was 55.50% per year. And the median was 55.50% per year.
Back to Basics: PS Ratio
Y-mAbs Therapeutics PS Ratio Historical Data
The historical data trend for Y-mAbs Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Y-mAbs Therapeutics's PS Ratio
For the Biotechnology subindustry, Y-mAbs Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Y-mAbs Therapeutics's PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Y-mAbs Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Y-mAbs Therapeutics's PS Ratio falls into.
Y-mAbs Therapeutics PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Y-mAbs Therapeutics's Share Price of today is $14.71. Y-mAbs Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.94.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Y-mAbs Therapeutics (NAS:YMAB) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Y-mAbs Therapeutics PS Ratio Related Terms
Thank you for viewing the detailed overview of Y-mAbs Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Y-mAbs Therapeutics (Y-mAbs Therapeutics) Business Description
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas. The vast majority of the Company's product sales are generated in the United States with additional sales outside the United States in China and Israel through sublicenses and distribution agreements.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
YMAB has been successfully added to your 